{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:43:01Z","timestamp":1790062981054,"version":"4.0.1"},"reference-count":44,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.3892\/ijo.2017.3870","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T12:01:04Z","timestamp":1486641664000},"page":"1044-1052","source":"Crossref","is-referenced-by-count":16,"title":["Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma"],"prefix":"10.3892","volume":"50","author":[{"given":"Sian","family":"Cregan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Breslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Wennstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"MacDonagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinaria","family":"Albadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"O'byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Cuffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"key20180107175650_b1-ijo-50-03-1044","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"key20180107175650_b2-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"716724A","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"key20180107175650_b3-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1539\/joh.16-2002-ST","article-title":"The global health dimensions of asbestos and asbestos-related diseases","volume":"58","author":"Ramazzini","year":"2016","journal-title":"J Occup Health"},{"key":"key20180107175650_b4-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/1403494815596500","article-title":"Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden","volume":"43","author":"J\u00e4rvholm","year":"2015","journal-title":"Scand J Public Health"},{"key":"key20180107175650_b5-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10408440903044928","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005","volume":"39","author":"Price","year":"2009","journal-title":"Crit Rev Toxicol"},{"key":"key20180107175650_b6-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.bjc.6605781","article-title":"Projection of mesothelioma mortality in Britain using Bayesian methods","volume":"103","author":"Tan","year":"2010","journal-title":"Br J Cancer"},{"key":"key20180107175650_b7-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: Facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"key":"key20180107175650_b8-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/oemed-2015-103074","article-title":"Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden","volume":"73","author":"Gilham","year":"2016","journal-title":"Occup Environ Med"},{"key":"key20180107175650_b9-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.canep.2015.08.007","article-title":"The next mesothelioma wave: Mortality trends and forecast to 2030 in Brazil","volume":"39","author":"Algranti","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"Suppl 5","key":"key20180107175650_b10-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"key20180107175650_b11-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107175650_b12-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107175650_b13-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/B978-0-12-800206-3.00009-4","article-title":"Epigenetic Therapy in Lung Cancer and Mesothelioma","volume-title":"Epigenetic Cancer Therapy","author":"Baird","year":"2015","edition":"1st"},{"key":"key20180107175650_b14-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"a019505","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20180107175650_b15-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-4939-1804-1_12","article-title":"Methylation profile landscape in mesothelioma: Possible implications in early detection, disease progression, and therapeutic options","volume":"1238","author":"Zhang","year":"2015","journal-title":"Methods Mol Biol"},{"key":"key20180107175650_b16-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107175650_b17-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180107175650_b18-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3892\/ijo.2016.3335","article-title":"KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma","volume":"48","author":"Cregan","year":"2016","journal-title":"Int J Oncol"},{"key":"key20180107175650_b19-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","article-title":"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors","volume":"6","author":"Sacco","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107175650_b20-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.it.2015.12.004","article-title":"Pleiotropic functions of H3K27Me3 demethylases in immune cell differentiation","volume":"37","author":"Bosselut","year":"2016","journal-title":"Trends Immunol"},{"key":"key20180107175650_b21-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107175650_b22-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ceb.2015.10.003","article-title":"PRC2 mediated H3K27 methylations in cellular identity and cancer","volume":"37","author":"Conway","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"key20180107175650_b23-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","article-title":"Polycomb repressor complex-2 is a novel target for mesothelioma therapy","volume":"18","author":"Kemp","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107175650_b24-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"key20180107175650_b25-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nature06145","article-title":"UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development","volume":"449","author":"Agger","year":"2007","journal-title":"Nature"},{"key":"key20180107175650_b26-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"18439","DOI":"10.1073\/pnas.0707292104","article-title":"Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases","volume":"104","author":"Hong","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107175650_b27-ijo-50-03-1044","first-page":"237","article-title":"Histone demethylase JMJD3 at the intersection of cellular senescence and cancer","volume":"1865","author":"Perrigue","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"key20180107175650_b28-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.critrevonc.2012.11.008","article-title":"Histone lysine demethylases in breast cancer","volume":"86","author":"Paolicchi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107175650_b29-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/1471-2407-12-470","article-title":"Expression and significance of histone H3K27 demethylases in renal cell carcinoma","volume":"12","author":"Shen","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180107175650_b30-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature11262","article-title":"A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response","volume":"488","author":"Kruidenier","year":"2012","journal-title":"Nature"},{"key":"key20180107175650_b31-ijo-50-03-1044","article-title":"Cell viability assays","volume-title":"Assay Guidance Manual (Internet)","author":"Riss","year":"2004"},{"key":"key20180107175650_b32-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1593\/neo.07112","article-title":"Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles","volume":"9","author":"Rhodes","year":"2007","journal-title":"Neoplasia"},{"key":"key20180107175650_b33-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"key20180107175650_b34-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"key20180107175650_b35-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cell.2007.08.019","article-title":"The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing","volume":"130","author":"De Santa","year":"2007","journal-title":"Cell"},{"key":"key20180107175650_b36-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"key20180107175650_b37-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J Transl Med"},{"key":"key20180107175650_b38-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.gde.2016.03.010","article-title":"Histone demethylases in physiology and cancer: A tale of two enzymes, JMJD3 and UTX","volume":"36","author":"Arcipowski","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"key20180107175650_b39-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/resp.12351","article-title":"A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma","volume":"19","author":"Lansley","year":"2014","journal-title":"Respirology"},{"key":"key20180107175650_b40-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1562\/0031-8655(2003)078<0075:ESCLIM>2.0.CO;2","article-title":"Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photo-dynamic therapy","volume":"78","author":"Yom","year":"2003","journal-title":"Photochem Photobiol"},{"key":"key20180107175650_b41-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2362.2000.00632.x","article-title":"Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: Cytokine patterns and acute-phase protein response","volume":"30","author":"Stam","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"key20180107175650_b42-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"key20180107175650_b43-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"key20180107175650_b44-ijo-50-03-1044","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Ann Oncol"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2017.3870\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T04:55:24Z","timestamp":1601614524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2017.3870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,2,9]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.3892\/ijo.2017.3870"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2017.3870","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}